See all

    You Don't Need to Look to the Night Sky to See the Little Tipper

    • 2022/05/18
    • by Sarah Binns

    A mere 21% of Americans would like to abolish the institution of tipping in restaurants. Survey research. Data science.

    Read more

    What to Expect When You’re Expecting Inflation

    • 2021/06/04
    • by Cory Manento

    Middle-income households are particularly likely to be feeling the inflation heat; those with incomes between $50k-100k are 5% more likely than the ...

    Read more

    The Gender “Return to Normal” Gap

    • 2021/06/04
    • by Cory Manento

    Men think we are about a year away from returning to normal economic activity, while women predict it will take about 17 months.

    Read more

    Tesla Stock: Asset Bubble or Champagne Bubble?

    • 2021/04/21
    • by Catherine Wagner

    Despite comprising a tiny portion of the US personal vehicle fleet today, 30% of Americans have considered purchasing an electric vehicle in the past two ...

    Read more

    Easy Come, (Not So) Easy Go

    • 2021/04/21
    • by Kyle Block

    As of early April, 67% of Americans report their household has received a stimulus check.

    Read more

    Ramp Up to Get Down

    • 2021/02/26
    • by Brendon Ellis

    As of early February, Americans predict more than a year and a half before we reach herd immunity or resume normal economic activity.

    Read more

    GameStop Won’t Stop

    • 2021/02/11
    • by Brendon Ellis

    For perspective, 61% of Americans do not engage in any type of stonk stock trading — either individually or through a brokerage.

    Read more

    Herd Mentality

    • 2021/01/29
    • by Brendon Ellis

    Something to keep a careful watch on is the 18% of Americans who report they do not plan to get vaccinated, imperiling the lofty but achievable goal of ...

    Read more

    Are We There Yet? … Actually, Yes, Almost

    • 2020/11/19
    • by Brendon Ellis

    In the past two weeks, both Pfizer and Moderna reported very promising results of their Phase III clinical trials.

    Read more